Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19.
Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari JP, Pang AP, Sugai C, Francisco EB, Pise A, Rodrigues H, Ryou M, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Aklin E, Ndhlovu L, Sacha JB. Patterson BK, et al. Among authors: lalezari jp. medRxiv [Preprint]. 2020 May 5:2020.05.02.20084673. doi: 10.1101/2020.05.02.20084673. medRxiv. 2020. PMID: 32511656 Free PMC article. Preprint.
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.
Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J, Pang APS, Sugai C, Mahyari E, Francisco EB, Pise A, Rodrigues H, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Bimber BN, Plassmeyer M, Gupta R, Alpan O, O'Halloran JA, Mudd PA, Akalin E, Ndhlovu LC, Sacha JB. Patterson BK, et al. Int J Infect Dis. 2021 Feb;103:25-32. doi: 10.1016/j.ijid.2020.10.101. Epub 2020 Nov 10. Int J Infect Dis. 2021. PMID: 33186704 Free PMC article.
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
Agresti N, Lalezari JP, Amodeo PP, Mody K, Mosher SF, Seethamraju H, Kelly SA, Pourhassan NZ, Sudduth CD, Bovinet C, ElSharkawi AE, Patterson BK, Stephen R, Sacha JB, Wu HL, Gross SA, Dhody K. Agresti N, et al. Among authors: lalezari jp. J Transl Autoimmun. 2021;4:100083. doi: 10.1016/j.jtauto.2021.100083. Epub 2021 Jan 6. J Transl Autoimmun. 2021. PMID: 33521616 Free PMC article. Review.
Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species.
Chang XL, Reed JS, Webb GM, Wu HL, Le J, Bateman KB, Greene JM, Pessoa C, Waytashek C, Weber WC, Hwang J, Fischer M, Moats C, Shiel O, Bochart RM, Crank H, Siess D, Giobbi T, Torgerson J, Agnor R, Gao L, Dhody K, Lalezari JP, Bandar IS, Carnate AM, Pang AS, Corley MJ, Kelly S, Pourhassan N, Smedley J, Bimber BN, Hansen SG, Ndhlovu LC, Sacha JB. Chang XL, et al. Among authors: lalezari jp. PLoS Pathog. 2022 Mar 31;18(3):e1010396. doi: 10.1371/journal.ppat.1010396. eCollection 2022 Mar. PLoS Pathog. 2022. PMID: 35358290 Free PMC article.
Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes.
Cohen OJ, Pantaleo G, Holodniy M, Fox CH, Orenstein JM, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, Cohn J, Novak R, McMahon D, Bilello J, Fauci AS. Cohen OJ, et al. J Infect Dis. 1996 Apr;173(4):849-56. doi: 10.1093/infdis/173.4.849. J Infect Dis. 1996. PMID: 8603962 Clinical Trial.
A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.
de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC, Shahmanesh M, Kinghorn G, Beutner KR, Patel R, Drehobl MA, Horner P, Kurtz TO, McDermott S, Wald A, Corey L. de Bruyn G, et al. Vaccine. 2006 Feb 13;24(7):914-20. doi: 10.1016/j.vaccine.2005.08.088. Epub 2005 Sep 21. Vaccine. 2006. PMID: 16213066 Clinical Trial.
Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.
Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, et al. Cohen OJ, et al. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6017-21. doi: 10.1073/pnas.92.13.6017. Proc Natl Acad Sci U S A. 1995. PMID: 7597072 Free PMC article. Clinical Trial.
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group. Priddy FH, et al. Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993. Clin Infect Dis. 2008. PMID: 18433307 Clinical Trial.
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study. Ferenci P, et al. N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4. N Engl J Med. 2014. PMID: 24795200 Free article. Clinical Trial.
72 results